Full-Time

Associate Scientist / Scientist 1

Computational Test Development

Precede Biosciences

Precede Biosciences

51-200 employees

Epigenomic liquid biopsy for cancer.

Compensation Overview

$110k - $150k/yr

Boston, MA, USA

Hybrid

Hybrid work in Boston is required.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Python
Data Visualization
R
AWS
Biostatistics
Data Analysis

Get referred to Precede Biosciences

See people who can refer or advise you

Requirements
  • A Master of Science degree in computational biology, bioinformatics, biostatistics, or a closely related quantitative field, plus 3–4 years of industry or post-graduate research experience in a data-intensive biological or biomedical setting.
  • Strong proficiency in R and Python for data analysis, visualization, and reproducible reporting, including writing, owning, and documenting code.
  • Experience with cloud computing environments such as Amazon Web Services for running scalable analyses.
  • Demonstrated ability to execute analytical plans with precision and efficiency while managing multiple tasks without compromising quality or documentation standards.
  • Familiarity with next-generation sequencing data types and standard processing pipelines, including alignment, quality control, and coverage analysis or equivalent.
  • Ability to communicate clearly and in an organized manner through written documentation, results presentations, and cross-functional interactions.
  • Ability to work in a fast-paced startup environment, follow defined protocols, and contribute ideas for improvement.
Responsibilities
  • Execute data analyses supporting assay characterization across multiple epigenomic and next-generation sequencing-based diagnostic tests, from raw data processing through performance metric generation.
  • Design and implement quality assessment frameworks to evaluate assay and pipeline performance, including quality control metric definition, threshold setting, and failure mode identification.
  • Run and interpret validation experiments in coordination with wet-lab and senior computational team members, contributing to study execution against predefined protocols.
  • Pursue defined research questions semi-independently by scoping problems, designing analytical approaches, executing analyses, and returning well-documented results.
  • Design and run in silico simulations to model assay behavior under variable conditions, including signal dropout, coverage non-uniformity, and input DNA variability.
  • Develop and apply statistical approaches to threshold setting and performance boundary definition, supporting limit-of-detection and analytical-range characterization.
  • Systematically explore parameter sensitivity across bioinformatics pipelines to assess model robustness and inform feature selection.
  • Produce thorough documentation of analysis code, methods, results, and interpretation to the standard required under design controls.
  • Contribute to authoring standard operating procedures and analytical summary reports.
  • Partner with wet-lab scientists to ensure computational analyses are grounded in experimental reality and results are communicated in accessible, actionable terms.
  • Present analytical findings in team meetings and cross-functional settings.
  • Share code and knowledge openly and proactively within the team.
Desired Qualifications
  • A Ph.D. degree.
  • Exposure to regulated environments, including Clinical Laboratory Improvement Amendments, College of American Pathologists, Food and Drug Administration in vitro diagnostics, or design controls.
  • Experience with epigenomic data types such as methylation, cell-free DNA, chromatin accessibility, or chromatin immunoprecipitation sequencing.
  • Familiarity with statistical thresholding or limit-of-detection frameworks for diagnostic applications.
  • Experience contributing to standard operating procedures, validation reports, or other regulated documentation.

Precede Biosciences uses a blood test to read epigenomic signals in plasma. It analyzes circulating chromatin and the DNA methylome from a single milliliter of blood to determine the activation status of about 20,000 gene promoters and 1 million gene enhancers, providing a transcriptional biology view of disease. The platform supports drug development through Research Use Only partnerships with biopharmaceutical companies and academia, and aims to develop clinical blood-based tests that can replace invasive tissue biopsies for guiding precision medicines in cancers such as breast, lung, prostate, and colorectal. Unlike purely genomic tests, this approach focuses on epigenomic regulation to reveal disease biology, treatment response, and resistance. The company seeks to help identify therapeutic targets and mechanisms driving outcomes, with a goal of accelerating biomarker discovery and enabling non-invasive, dynamic insights into cancer biology.

Company Size

51-200

Company Stage

Series B

Total Funding

$140.5M

Headquarters

Boston, Massachusetts

Founded

2021

Get referred to Precede Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • January 2026 financing raised $83.5 million, extending runway and investor credibility.
  • May 2026 ASCO data showed MET biology and resistance in advanced NSCLC.
  • April 2026 studies linked plasma readouts to endocrine response, supporting pharma partnerships.

What critics are saying

  • RUO-only sales through 2026 block clinical revenue and reimbursement.
  • Guardant Health, Foundation Medicine, and Grail own larger distribution and evidence budgets.
  • If AACR and ASCO data fail prospective validation, Precede Bio Insight stalls commercially.

What makes Precede Biosciences unique

  • Precede Bio Insight launched April 2026, inferring gene expression from 1 mL plasma.
  • Dana-Farber, Fred Hutchinson, Genentech, and Emory validated tumor biology applications.
  • It spans drug development, target expression, pathway activity, and resistance mechanisms beyond genomics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Stock Options

Company Equity

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Mentorship Program

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
May 31st, 2026
Precede Biosciences' plasma test achieves 97% accuracy in detecting MET expression in advanced NSCLC

Precede Biosciences presented data at the 2026 American Society of Clinical Oncology Annual Meeting demonstrating its Precede Bio Insight platform can decode MET-driven biology and resistance in advanced non-small cell lung cancer using just one millilitre of plasma. The company's plasma MET test showed high concordance with tissue testing in EGFR-mutated NSCLC patients following progression on first-line targeted therapy. Baseline and longitudinal profiling in MET ex14 skipping NSCLC identified biology associated with therapeutic sensitivity and resistance, including MET pathway activity and neuroendocrine lineage plasticity. The functional liquid biopsy platform provides transcriptional biology analysis beyond genomics, assessing target expression, pathway activity and cell-state changes from blood samples. Precede Biosciences aims to improve drug development efficiency and enable minimally invasive diagnostics aligned to disease biology.

Associated Press
Apr 21st, 2026
Precede Biosciences launches genome-wide liquid biopsy to predict cancer therapy response from 1 mL plasma

Precede Biosciences has launched Precede Bio Insight, a genome-wide liquid biopsy platform that decodes transcriptional biology from cell-free DNA using just 1 millilitre of plasma. The product enables quantitative inference of gene expression, pathway activity and cell states with concordance to tissue-based measurements. The launch, announced at the American Association for Cancer Research 2026 Annual Meeting, is supported by studies conducted with Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, Genentech and Emory University School of Medicine. Research demonstrated the platform's ability to predict therapeutic response to endocrine therapies, assess target expression for emerging treatments including radioligand therapies and antibody-drug conjugates, and reveal resistance mechanisms in breast and prostate cancer. Precede Bio Insight is now available for research and development collaborations.

The Newberg Graphic
Apr 21st, 2026
Precede Biosciences launches Precede Bio Insight(TM), a genome-wide liquid biopsy for functional tumor biology at AACR 2026.

Precede Biosciences launches Precede Bio Insight(TM), a genome-wide liquid biopsy for functional tumor biology at AACR 2026. GlobeNewswire | Precede Biosciences, Inc. Today at 11:30am PDT * Precede Bio Insight debuts as a first-of-its-kind product enabling genome-wide inference of gene expression, pathway activity, and cell states from just 1 mL of plasma * AACR studies demonstrate the ability to predict therapeutic response, reveal resistance mechanisms, and quantitatively assess target expression and pathway activity with concordance to tissue * Data span breast and prostate cancer and highlight applications across next-generation endocrine therapies and emerging targeted modalities, including radioligand therapies and antibody-drug conjugates - areas with extensive global clinical trial activity BOSTON, April 21, 2026 (GLOBE NEWSWIRE) - Precede Biosciences, a company powering next-generation precision medicine through its comprehensive epigenomic liquid biopsy platform, today announced the launch of Precede Bio Insight(TM) and the presentation of new data at the American Association for Cancer Research (AACR) 2026 Annual Meeting, held April 17-22 in San Diego, California. Precede Bio Insight is a first-of-its-kind product that decodes genome-wide transcriptional biology from cell-free DNA in just 1 mL of plasma, enabling quantitative inference of gene expression, pathway activity, and cell states with concordance to tissue-based measurements. By simultaneously assessing therapeutic targets, resistance pathways, and tumor lineage programs in a single assay, Insight provides a functional, systems-level view of tumor biology to inform drug development and patient selection. "Cancer clinical trials enroll close to 300,000 patients annually, yet access to real-time functional tumor biology remains limited, constraining mechanistic insight and the ability to refine therapeutic development strategies," said Rehan Verjee, Chief Executive Officer of Precede Biosciences. "With the launch of Precede Bio Insight, R&D teams can now serially access genome-wide visibility across targets, pathways, and cell states from just 1 mL of plasma, enabling smarter decisions about patient selection, treatment combinations, and sequencing." The Insight launch is supported by a growing body of clinical evidence, including the three studies presented at AACR 2026, conducted in collaboration with Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, Genentech, and Emory University School of Medicine. Across these studies, profiling from plasma: * Correlated with tissue-based measures of tumor biology, including RNA expression and protein target expression * Enabled multiplexed, quantitative assessment of therapeutically relevant targets and pathways such as DLL3, CEACAM5, and the ER pathway * Captured tumor heterogeneity and lineage plasticity, including continuous states of neuroendocrine differentiation * Predicted response to endocrine therapy, including next-generation SERDs, through a plasma-based functional measure of tumor ER pathway dependence * Provided early pharmacodynamic readout of treatment response * Revealed resistance mechanisms beyond genomic alterations AACR 2026 Presentations * Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid biopsy stratifies endocrine therapy (ET) responders with metastatic breast cancer (MBC) * A liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2− advanced breast cancer * Plasma-based comprehensive epigenomic profiling enables multiplexed prediction of target gene expression and detection of resistance mechanisms Data presentations are available in the presentations section of the company website at www.precede.bio. Precede Bio Insight is available for research and development collaborations. To learn more or to start a partnership discussion, visit insight.precede.bio. About Precede Biosciences Precede Biosciences is a precision diagnostics and data company redefining what can be learned from a simple blood draw. By unlocking genome-wide transcriptional biology through a novel, comprehensive epigenomics approach, the company enables researchers and clinicians to better understand disease biology in real time. By partnering with developers of new medicines and advancing its own diagnostic tests, Precede Bio is working toward a future in which drug development is more efficient and patients receive minimally invasive diagnostics and treatments aligned to the biology of their disease. To learn more, visit www.precede.bio or follow Newberggraphic on LinkedIn. About Precede Bio Insight(TM) Precede Bio Insight is a first-of-its-kind, research-use-only (RUO) product that enables genome-wide liquid biopsy of gene expression from just 1 mL of plasma. Powered by comprehensive epigenomic profiling of cell-free DNA and advanced machine learning, Insight generates quantitative measures of tumor and immune transcriptional biology, including target expression, pathway activity, and cell states. This approach provides a unified, functional view of tumor biology to inform critical R&D decisions, including patient selection and the design of more precise treatment combinations and sequencing strategies. To learn more, visit insight.precede.bio. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Benzinga
Jan 12th, 2026
Precede Biosciences raises $83.5M to scale precision diagnostics platform for next-generation cancer therapies

Precede Biosciences, a precision diagnostics company focused on enabling next-generation precision medicines, has secured $83.5 million in total financing, comprising $63.5 million in Series B equity and a $20 million non-dilutive credit facility. The Boston-based company's platform supports development and clinical use of cancer therapies where target expression and pathway activity serve as defining biomarkers, including drug-, radio-, and immune-conjugates. The funding will scale operations to meet growing demand from developers of these precision medicines. New investors include Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Mirae Asset Capital, 28 Capital and Alexandria Venture Investments, alongside existing backers. The expanded investor base brings expertise in diagnostics commercialisation and health system adoption.

Boone Newspapers
Oct 21st, 2023
Precede Biosciences Unveils Groundbreaking Clinical Data for its Pioneering Liquid Biopsy Platform at ESMO 2023 and Simultaneously Publishes in Nature Medicine

Precede Biosciences unveils groundbreaking clinical data for its pioneering Liquid Biopsy platform at ESMO 2023 and simultaneously publishes in Nature Medicine.